Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
A clinically meaningful benefit in radiographic progression-free survival was provided by olaparib in men with metastatic castration-resistant prostate cancer who had progressed on prior treatment with new hormonal anticancer treatments
Ivosidenib may be a new treatment option for rare cholangiocarcinoma in patients with an isocitrate dehydrogenase 1 mutation
Survival benefit following immune blockade also differs in men and women when the agent is administered as monotherapy or in combination with chemotherapy
Fit and unfit elderly patients derive different benefit from systemic treatment for HNSCC
Second-line treatment with lenvatinib shows promising anti-tumour activity
Neoadjuvant therapy with pembrolizumab plus chemotherapy provides greater anti-tumour activity than placebo plus chemotherapy in patients with early stage triple negative breast cancer
Adding veliparib to carboplatin and paclitaxel doubled the 3-year progression-free survival rate over carboplatin and paclitaxel
Exploratory analysis of FLAURA data demonstrates that longitudinal ctDNA monitoring can provide early detection of disease progression and/or resistance in advanced NSCLC
The results from LIBRETTO-001 trial
TRIUMPH and MOUNTAINEER demonstrate promising clinical benefit for dual HER2 blockade in patients with HER2-amplified metastatic CRC; however, HERACLES-B did not meet the primary endpoint
A subset of patients with MSI-H tumours demonstrated superior benefit from pembrolizumab, both in combination with chemotherapy or as monotherapy
Differences in patient outcome were observed in four molecular subgroups after adjuvant chemotherapy plus radiotherapy or radiotherapy
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
